Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:APGE NASDAQ:APLS NASDAQ:CRSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.96+6.3%$3.63$1.94▼$6.51$1.51B1.024.49 million shs3.02 million shsAPGEApogee Therapeutics$84.29+1.2%$79.18$34.34▼$95.32$5.22B0.69958,842 shs89,491 shsAPLSApellis Pharmaceuticals$41.02+0.1%$29.59$16.10▼$41.05$5.25B-0.244.53 million shs936,636 shsCRSPCRISPR Therapeutics$53.76+2.6%$52.41$33.50▼$78.48$5.18B1.741.87 million shs526,385 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+5.19%+12.15%+32.39%+42.51%+112.79%APGEApogee Therapeutics+3.15%-2.44%-1.24%+28.38%+111.45%APLSApellis Pharmaceuticals+0.02%-0.05%+1.39%+76.98%+105.06%CRSPCRISPR Therapeutics+1.45%+0.61%+5.80%+4.41%+39.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.96+6.3%$3.63$1.94▼$6.51$1.51B1.024.49 million shs3.02 million shsAPGEApogee Therapeutics$84.29+1.2%$79.18$34.34▼$95.32$5.22B0.69958,842 shs89,491 shsAPLSApellis Pharmaceuticals$41.02+0.1%$29.59$16.10▼$41.05$5.25B-0.244.53 million shs936,636 shsCRSPCRISPR Therapeutics$53.76+2.6%$52.41$33.50▼$78.48$5.18B1.741.87 million shs526,385 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+5.19%+12.15%+32.39%+42.51%+112.79%APGEApogee Therapeutics+3.15%-2.44%-1.24%+28.38%+111.45%APLSApellis Pharmaceuticals+0.02%-0.05%+1.39%+76.98%+105.06%CRSPCRISPR Therapeutics+1.45%+0.61%+5.80%+4.41%+39.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.71Moderate Buy$8.1764.82% UpsideAPGEApogee Therapeutics 2.78Moderate Buy$112.7333.75% UpsideAPLSApellis Pharmaceuticals 2.04Hold$34.89-14.92% DownsideCRSPCRISPR Therapeutics 2.53Moderate Buy$64.5320.03% UpsideCurrent Analyst Ratings BreakdownLatest ABCL, APLS, APGE, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/5/2026ABCLAbCellera Biologics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.005/1/2026APGEApogee Therapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.005/1/2026APGEApogee Therapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.004/20/2026ABCLAbCellera Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026APGEApogee Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026APLSApellis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.004/10/2026ABCLAbCellera Biologics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.004/9/2026ABCLAbCellera Biologics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/2/2026APLSApellis Pharmaceuticals Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$75.13M20.13N/AN/A$3.23 per share1.53APGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/AAPLSApellis Pharmaceuticals$1.00B5.23$0.21 per share196.04$2.93 per share14.00CRSPCRISPR Therapeutics$3.51M1,476.94N/AN/A$20.17 per share2.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.41M-$0.49N/AN/AN/A-198.37%-15.05%-10.92%5/11/2026 (Estimated)APGEApogee Therapeutics-$255.84M-$4.22N/AN/AN/AN/A-36.77%-34.87%5/11/2026 (Estimated)APLSApellis Pharmaceuticals$22.39M$0.13315.52N/AN/A2.23%8.20%2.38%5/6/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.52N/AN/AN/A-13,856.54%-25.53%-21.66%5/11/2026 (Estimated)Latest ABCL, APLS, APGE, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026ABCLAbCellera Biologics-$0.22N/AN/AN/A$5.70 millionN/A5/11/2026Q1 2026APGEApogee Therapeutics-$1.12N/AN/AN/AN/AN/A5/6/2026Q1 2026APLSApellis Pharmaceuticals-$0.38N/AN/AN/A$203.58 millionN/A5/5/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/2/2026Q4 2025APGEApogee Therapeutics-$1.05-$1.03+$0.02-$1.03N/AN/A2/24/2026Q4 2025ABCLAbCellera Biologics-$0.18-$0.03+$0.15-$0.03$6.31 million$44.85 million2/24/2026Q4 2025APLSApellis Pharmaceuticals-$0.39$0.47+$0.86-$0.45$199.28 million$199.91 million2/13/2026Q4 2025CRSPCRISPR Therapeutics-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A11.3211.32APGEApogee TherapeuticsN/A26.5726.57APLSApellis Pharmaceuticals0.983.142.70CRSPCRISPR TherapeuticsN/A13.3213.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%APGEApogee Therapeutics79.04%APLSApellis Pharmaceuticals96.29%CRSPCRISPR Therapeutics69.20%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%APGEApogee Therapeutics24.30%APLSApellis Pharmaceuticals6.80%CRSPCRISPR Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500305.27 million217.04 millionOptionableAPGEApogee Therapeutics9161.85 million46.82 millionOptionableAPLSApellis Pharmaceuticals770128.02 million119.32 millionOptionableCRSPCRISPR Therapeutics46096.43 million92.48 millionOptionableABCL, APLS, APGE, and CRSP HeadlinesRecent News About These CompaniesCRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference3 hours ago | globenewswire.comFY2028 EPS Estimates for CRSP Decreased by Analyst3 hours ago | marketbeat.comEquities Analysts Offer Predictions for CRSP FY2027 Earnings3 hours ago | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 6.1% - What's Next?May 5 at 4:29 PM | marketbeat.comCRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesMay 5 at 3:53 PM | finance.yahoo.comVRTX's Q1 Earnings Beat Estimates, New Products Aid Sales GrowthMay 5 at 3:53 PM | finance.yahoo.comCRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesMay 5 at 9:21 AM | zacks.comCRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesMay 4 at 12:06 AM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesMay 4 at 8:30 PM | zacks.comCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 4 at 7:06 PM | finance.yahoo.comCRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.06 EPSMay 4 at 6:25 PM | marketbeat.comCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 4 at 4:30 PM | globenewswire.comCRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on MondayMay 4 at 3:21 AM | marketbeat.comPictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSPMay 3 at 5:39 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP)May 1, 2026 | theglobeandmail.comUBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSPMay 1, 2026 | marketbeat.comMirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 29, 2026 | zacks.comGSK (GSK) Tops Q1 Earnings and Revenue EstimatesApril 29, 2026 | zacks.comWhy the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained TodayApril 28, 2026 | finance.yahoo.comWhy the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained TodayApril 28, 2026 | zacks.comCRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 28, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026ABCL, APLS, APGE, and CRSP Company DescriptionsAbCellera Biologics NASDAQ:ABCL$4.96 +0.30 (+6.33%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Apogee Therapeutics NASDAQ:APGE$84.28 +1.00 (+1.19%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Apellis Pharmaceuticals NASDAQ:APLS$41.02 +0.05 (+0.11%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$53.76 +1.38 (+2.63%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
